Larimar Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• CTI-1601 · Neurology
  CTI-1601 is a gene therapy that aims to restore motor neuron function in patients with amyotrophic lateral sclerosis (ALS).

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Larimar Therapeutics, Inc. portfolio CI brief
• Larimar Therapeutics, Inc. pipeline updates RSS